Fintel reports that on September 12, 2023, Goldman Sachs maintained coverage of Ideaya Biosciences (NASDAQ:IDYA) with a Buy recommendation.
Analyst Price Forecast Suggests 21.84% Upside
As of August 31, 2023, the average one-year price target for Ideaya Biosciences is 35.78. The forecasts range from a low of 30.30 to a high of $44.10. The average price target represents an increase of 21.84% from its latest reported closing price of 29.37.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ideaya Biosciences is 17MM, a decrease of 61.80%. The projected annual non-GAAP EPS is -2.65.
What is the Fund Sentiment?
There are 322 funds or institutions reporting positions in Ideaya Biosciences. This is an increase of 22 owner(s) or 7.33% in the last quarter. Average portfolio weight of all funds dedicated to IDYA is 0.39%, an increase of 16.73%. Total shares owned by institutions increased in the last three months by 26.57% to 59,514K shares. 
The put/call ratio of IDYA is 0.70, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 5,683K shares representing 9.87% ownership of the company. In it's prior filing, the firm reported owning 2,455K shares, representing an increase of 56.80%. The firm increased its portfolio allocation in IDYA by 202.11% over the last quarter.
Federated Hermes holds 3,390K shares representing 5.89% ownership of the company. In it's prior filing, the firm reported owning 2,865K shares, representing an increase of 15.49%. The firm increased its portfolio allocation in IDYA by 102.61% over the last quarter.
Avidity Partners Management holds 2,986K shares representing 5.19% ownership of the company. In it's prior filing, the firm reported owning 3,673K shares, representing a decrease of 23.03%. The firm increased its portfolio allocation in IDYA by 46.38% over the last quarter.
Canaan Partners X holds 2,661K shares representing 4.62% ownership of the company. No change in the last quarter.
Adage Capital Partners Gp, L.l.c. holds 2,575K shares representing 4.47% ownership of the company. In it's prior filing, the firm reported owning 2,677K shares, representing a decrease of 3.94%. The firm increased its portfolio allocation in IDYA by 59.51% over the last quarter.
Ideaya Biosciences Background Information
(This description is provided by the company.)
IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
